摘要
目的探讨派特灵宫颈用药对人乳头瘤病毒(HPV) E6/E7 mRNA的影响及临床意义。方法选取2015年1月～2016年10月在我院行阴道镜下宫颈活检病理为CINⅢ及以下病变,并且HPV E6/E7 mRNA持续3个月阳性的患者198例,根据治疗方式不同归为非手术及手术组,两组再随机细分为派特灵用药组及对照组。非手术组共102例,其中用药组48例,对照组54例;手术组共96例,其中用药组46例,对照组50例。用药组予派特灵治疗1个疗程,对照组随访观察,于第6个月、9个月、12个月复查HPV E6/E7 mRNA。分析比较HPV E6/E7 mRNA转阴率、有效率及拷贝水平变化。结果非手术用药组第6、9、12个月转阴率分别为45.8%、62.5%、75.0%,有效率分别为81.3%、87.5%、89.6%,显著高于对照组(P<0.05)。手术用药组第6、9、12个月转阴率分别为71.7%、80.4%、82.6%,有效率分别为84.8%、91.3%、89.1%,显著高于对照组(P<0.05)。非手术用药组第6个月、9个月、12个月HPV E6/E7 mRNA拷贝水平下降幅度为56.8%、72.5%、71.5%,手术用药组HPV E6/E7 mRNA拷贝水平下降幅度为74.2%、82.8%、83.9%,均优于对照组(P<0.05)。结论派特灵宫颈用药可以降低HPV E6/E7 mRNA拷贝水平,抑制E6/E7癌基因活性,降低宫颈癌发生风险。
Objective To investigate the effect and clinical significance of Paiteling cervical administration on human papillomavirus（HPV） E6/E7 mRNA. Methods From January 2015 to October 2016, the lesions with CIN Ⅲ and below which were given pathological examination of cervical biopsy under colposcopy in our hospital was selected, and 198 patients with HPV E6/E7 mRNA positive for 3 months were selected. According to different treatment methods, they were classified into non-surgical group and surgical group. The two groups were randomly further divided into Paiteling medication group and control group. 102 patients were in the non-surgical group. There were 48 patients in the medi- cation group and 54 patients in the control group; there were 96 cases in the surgery group, including 46 cases in the medication group and 50 cases in the control group. The medication group was given one course of treatment with Paiteling. The control group was followed up and given the re-examination of HPV E6/E7 mRNA at 6 months, 9 months, and 12 months. The HPV E6/E7 mRNA negative conversion rate, effective rate and copy level changes were analyzed and compared. Results The negative conversion rates in the 6th, 9th, and 12th months in the non-surgical medication group were 45.8%, 62.5%, and 75.0%, respectively. The effective rates were 81.3%, 87.5%, and 89.6%, re- spectively, significantly higher than those in the control group（P〈0.05）. The negative conversion rates in the surgical medication group at the 6th, 9th, and 12th months were 71.7%, 80.4%, and 82.6%, respectively. The effective rates were 84.8%, 91.3%, and 89.1%, respectively, which were significantly higher than those in the control group（P〈0.05）. The HPV E6/E7 mRNA copy levels were decreased by 56.8%, 72.5%, and 71.5% at the 6th, 9th, and 12th months in the non-surgical medication group. The HPV E6/E7 mRNA copy levels in the surgical medication group were decreased by 74.2%, 82.8%, and 83.9% respectively, which were all better than those in the control group�
作者
黄凌霄
郭敏
董晓霞
杨爱武
郑建琼
HUANG Lingxiao;GUO Min;DONG Xiaoxia;YANG Aiwu;ZHENG Jianqiong(Department of Gynecology and Obstetrics,Wenzhou People＇s Hospital in Zhejiang Province,Wenzhou 325000,China)
出处
《中国现代医生》
2018年第25期74-78,共5页
China Modern Doctor
基金
浙江省自然科学基金青年基金项目(LQ18H040002)
浙江省温州市公益性社会发展科技项目(Y20150225)
